Society for cardiovascular angiography and interventions 2010 and EuroPCR 2010: An update in interventional cardiology

JACC: Cardiovascular Interventions

Volumn 3, Issue 8, 2010, Pages 882-884

  Claessen, Bimmer E P M ^a,b   Henriques, José P S ^b   George, Jon C ^c   Dangas, George D ^a  

^a Department of Medicine   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c DEBORAH HEART AND LUNG CENTER   (United States)

Author keywords

drug eluting balloons; drug eluting stents; late breaking clinical trials; percutaneous valve repair

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ANGIOGRAPHY; ARTICLE; BARE METAL STENT; BIODEGRADABLE IMPLANT; CARDIOLOGY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HEART DEATH; HEART INFARCTION; HUMAN; MEDICAL SOCIETY; MITRAL VALVE REGURGITATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT; STENT THROMBOSIS; VASCULARIZATION;

EID: 78651270459     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.07.001     Document Type: Article

References (9)

1. Gray WA. Single-arm clinical study of the Zilver PTX drug-eluting peripheral stent: two-year interim results. Presented at: Society for Cardiovascular Angiography and Interventions 33rd Annual Scientific Sessions; May 7, 2010; San Diego, CA.
2. Feldman T. EVEREST II randomized clinical trial update: degenerative vs. functional MR 2-year outcomes. Presented at: EuroPCR 2010; May 25, 2010; Paris, France.
3. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). J Am Coll Cardiol 2006;48:e1-148.
4. Serruys PW. Twelve months primary endpoint results of the RESOLUTE all-comers trial: a randomised comparison of a Zotarolimus-eluting stent with an Everolimus-eluting stent for percutaneous coronary intervention. Presented at: EuroPCR 2010; May 25, 2010; Paris, France.
5. Abizaid A. 12-month results from the multicenter, randomised, NEVO-RES-I trial. Presented at: EuroPCR 2010; May 25, 2010; Paris, France.
6. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
7. Tanimoto S, Serruys PW, Thuesen L, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007;70:515-23.
8. Stella PR. Drug eluting balloons in coronary bifurcations: the Drug Eluting Balloon In BifUrcation Trial (DEBIUT). Presented at: EuroPCR 2010; May 25, 2010; Paris, France.
9. Cardiosource website. Available at: http://www.cardiosource.org. Accessed June 20, 2010.